

## PROVINCIAL FUNDING SUMMARY

### Ipilimumab (Yervoy) for Advanced Melanoma

pERC Recommendation: Recommend with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: May 2, 2012

This information is current as of August 4, 2016.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2012	Unresectable stage III or stage IV melanoma; ECOG 0-1; adequate hepatic and renal function; at least one prior systemic therapy; life expectancy of at least 4 months; access to a treatment centre with expertise to manage immune-mediated adverse reactions of ipilimumab. A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Funded	Oct 19, 2012	For the treatment of advanced melanoma (unresectable Stage III or IV melanoma) in patients who have received prior systemic therapy. July 2015 - not available following other immunotherapy (eg pembrolizumab, nivolumab)
SK	Funded	Sep 4, 2012	Completion of the SCA Treatment Evaluation Program (STEP) request form for each patient is required for treatment approval. Treatment of patients who have received at least one prior systemic therapy for advanced melanoma (unresectable stage III or metastatic) with a good performance status (ECOG 0 or 1). Ipilimumab induction is funded for four (4) doses at 3 mg/kg administered every 3 weeks. Induction therapy is discontinued if 4 doses cannot be administered within 16 weeks. If re-induction with a further 4 doses is being considered in patients who remain ECOG 0 or 1 and who have had stable disease for a minimum of 3 months following first induction or who achieved a partial or complete response to first induction, re-application and approval through STEP must be made.  Not approved for the following indication: First line treatment of advanced melanoma (unresectable stage III or metastatic)

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	Jul 1, 2012	<p>For the treatment of patients:            With unresectable or metastatic (Stage IIIC or IV) melanoma AND            With an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less AND            With anticipated life expectancy of more than 3 months AND            Who have received at least one line of systemic therapy for advanced melanoma OR            With intolerance to a previous line of systemic therapy for advanced melanoma.</p>
ON	Funded	Sep 13, 2012	<p>Initial treatment: For the treatment of unresectable stage 3 or 4 melanoma in patients who have received at least one systemic therapy for advanced melanoma. The patient has an ECOG <math>\leq 1</math>.</p> <p>Re-induction: At the time of disease progression, the patient has had stable disease for at least three months or has previously experienced a complete or partial response to ipilimumab. The patient has an ECOG <math>\leq 1</math>.</p> <p>Induction/Re-induction Dose: Ipilimumab 3mg/kg every 3 weeks for 4 doses</p> <p>Notes:            a. To be eligible for re-induction, a clinic note must be submitted to CCO documenting that at the time of disease progression, the patient has had stable disease for at least 3 months or the patient has previously experienced a complete or partial response to ipilimumab, and the patient has an ECOG <math>\leq 1</math>.            b. Ipilimumab is not funded if used in the first line treatment of unresectable Stage 3 or 4 melanoma, or if the patient has an ECOG <math>\geq 2</math>.</p>
NS	Funded	Jan 1, 2013	<p>Initial Treatment: As a single agent for the treatment of unresectable Stage III or IV melanoma in patients who have received at least one prior systemic treatment for advanced melanoma and ECOG performance status (PS) <math>\leq 1</math>.</p> <p>Retreatment: At the time of disease progression, re-induction may be considered if patients have had stable disease for at least three months or have previously experienced a complete or partial response to ipilimumab and ECOG PS <math>\leq 1</math>.</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NB	Funded	Feb 1, 2014	<p>Initial treatment: As a single agent for the treatment of unresectable stage III or IV melanoma in patients who have received at least one prior systemic therapy for advanced melanoma and have good performance status (ECOG <math>\leq</math> 1);</p> <p>Re-induction: At the time of disease progression, the patient has had stable disease for at least three months or has previously experienced a complete or partial response to ipilimumab. The patient has an ECOG <math>\leq</math> 1.</p>
NL	Funded	Jan 1, 2013	<p>For the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease</p>
PEI	Funded	Apr 8, 2014	<p>Initial Request: For the treatment of unresectable stage III or IV melanoma in patients who have received at least one systemic therapy for advanced melanoma and an ECOG <math>\leq</math> 1.</p> <p>Dosing Regimen: 3mg/kg every three weeks for four doses</p> <p>Re-Induction: At the time of disease progression, re-induction may be considered if patients have had stable disease for at least three months duration or have previously experienced a complete or partial response to ipilimumab and an ECOG of <math>\leq</math> 1.</p> <p>Dosing Regimen: 3mg/kg every three weeks for four doses</p> <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> <li>• ECOG <math>\geq</math> 2</li> <li>• First-line unresectable or metastatic stage III or IV melanoma.</li> </ul>